| Ms Sarai Christian Webb-vanderpoorten, LMFT | |
|
4715 24th Pl, Meridian, MS 39305-1686 | |
| (601) 696-6736 | |
| (601) 696-6778 |
| Full Name | Ms Sarai Christian Webb-vanderpoorten |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 4715 24th Pl, Meridian, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215084173 | NPI | - | NPPES |
| 579697 | Other | MS | VALUE OPTIONS |
| 611657600 | Other | MS | U.S. DEPT. OF LABOR |
| 74312880 | Other | MS | SEDGWICK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | T-0027 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Sarai Christian Webb-vanderpoorten, LMFT 4715 24th Pl, Meridian, MS 39305-1686 Ph: (601) 696-6736 | Ms Sarai Christian Webb-vanderpoorten, LMFT 4715 24th Pl, Meridian, MS 39305-1686 Ph: (601) 696-6736 |
News Archive
Patients who undergo MRI often suffer from elevated anxiety. Patient discomfort may cause poor image quality due to motion artifacts or early termination. Anxiolytic medications are currently used to reduce this anticipated anxiety , but animal-assisted therapy may be a non-invasive alternative treatment with fewer adverse effects, according to an exhibit being presented at the 2011 American Roentgen Ray Society's annual meeting.
Today, the International Rett Syndrome Foundation announced that it will provide $200,000 in 2009 to support a newly proposed clinical trial with a growth-factor based treatment for Rett Syndrome. The study will be carried out by a team of clinical trials specialists at the Boston Children's Hospital, led by Dr. Omar Khwaja MD, PhD and will be the first potentially disease modifying therapy ever to be tested in Rett syndrome patients.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
Precedent Health, Inc., a healthcare company focused on aligning physicians, hospitals and payers by building innovative provider networks, today announced the formal launch of the company. Funding was provided by Heritage Group, LLC, TEXO Ventures, LLC and members of the founding executive team. The company will have its headquarters in Nashville, TN along with a satellite office in Austin, TX.
› Verified 2 days ago
Evelyn D Walters, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1415 College Dr, Meridian, MS 39307 Phone: 601-483-4821 Fax: 601-485-0223 |